

Margaret M Madeleine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2318704/publications.pdf>

Version: 2024-02-01

36
papers

3,545
citations

361413

20
h-index

345221

36
g-index

36
all docs

36
docs citations

36
times ranked

5636
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1891.	7.4	1,176
2	Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. <i>Cancer</i> , 2004, 101, 270-280.	4.1	699
3	Risk of Human Papillomavirus-Associated Cancers Among Persons With AIDS. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1120-1130.	6.3	468
4	Cofactors With Human Papillomavirus in a Population-Based Study of Vulvar Cancer. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1516-1523.	6.3	155
5	Risk of cervical cancer associated with <i>Chlamydia trachomatis</i> antibodies by histology, HPV type and HPV cofactors. <i>International Journal of Cancer</i> , 2007, 120, 650-655.	5.1	121
6	Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk. <i>Cancer Research</i> , 2008, 68, 3532-3539.	0.9	111
7	Defining the genetic susceptibility to cervical neoplasia: A genome-wide association study. <i>PLoS Genetics</i> , 2017, 13, e1006866.	3.5	105
8	Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 1226-1234.	4.7	96
9	Human Leukocyte Antigen Class II and Cervical Cancer Risk: A Population-Based Study. <i>Journal of Infectious Diseases</i> , 2002, 186, 1565-1574.	4.0	83
10	Epidemiology of keratinocyte carcinomas after organ transplantation. <i>British Journal of Dermatology</i> , 2017, 177, 1208-1216.	1.5	67
11	Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 887-899.	2.5	42
12	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017, 66, 1739-1747.	12.1	38
13	Cervical and Vulvar Cancer Risk in Relation to the Joint Effects of Cigarette Smoking and Genetic Variation in Interleukin 2. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1790-1799.	2.5	37
14	Risk of Cervical Cancer Associated with Allergies and Polymorphisms in Genes in the Chromosome 5 Cytokine Cluster. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 199-207.	2.5	37
15	Genetic variation in the TLR and NF- κ B pathways and cervical and vulvar cancer risk: A population-based case-control study. <i>International Journal of Cancer</i> , 2014, 134, 437-444.	5.1	31
16	Nucleotide variation in <i>IL10</i> and <i>IL12</i> and their receptors and cervical and vulvar cancer risk: A hybrid case-parent triad and case-control study. <i>International Journal of Cancer</i> , 2013, 133, 201-213.	5.1	30
17	Risk of lip cancer after solid organ transplantation in the United States. <i>American Journal of Transplantation</i> , 2019, 19, 227-237.	4.7	25
18	Gynecologic cancers and solid organ transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1266-1277.	4.7	24

#	ARTICLE	IF	CITATIONS
19	Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 119.	2.8	23
20	A population-based case-control study of genetic variation in cytokine genes associated with risk of cervical and vulvar cancers. <i>Gynecologic Oncology</i> , 2015, 139, 90-96.	1.4	23
21	Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA). <i>JAMA Network Open</i> , 2019, 2, e190819.	5.9	23
22	HLA and KIR Associations of Cervical Neoplasia. <i>Journal of Infectious Diseases</i> , 2018, 218, 2006-2015.	4.0	22
23	Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants. <i>Cancer Medicine</i> , 2014, 3, 1440-1447.	2.8	19
24	Cohort Profile: The Skin Cancer After Organ Transplant Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1669-1677.	1.9	16
25	Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States. <i>Cancer</i> , 2018, 124, 2515-2522.	4.1	12
26	Parity and HLA alleles in risk of rheumatoid arthritis. <i>Chimerism</i> , 2011, 2, 11-15.	0.7	11
27	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2021, 42, 369-377.	2.8	11
28	Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US. <i>JAMA Dermatology</i> , 2022, 158, 414.	4.1	11
29	Natural Antibodies to Human Papillomavirus 16 and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3). <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 257-260.	1.9	9
30	Inequitable access to surveillance colonoscopy among Medicare beneficiaries with surgically resected colorectal cancer. <i>Cancer</i> , 2021, 127, 412-421.	4.1	5
31	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	1.3	4
32	Disparities in post-operative surveillance testing for metastatic recurrence among colorectal cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 638-649.	2.9	4
33	Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2255-2260.	2.5	3
34	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. <i>Cancer Investigation</i> , 2022, 40, 17-25.	1.3	2
35	Time and geographic variations in human papillomavirus vaccine uptake in Washington state. <i>Preventive Medicine</i> , 2021, 153, 106753.	3.4	1
36	Barriers to Human Papillomavirus Vaccine Series Completion among Insured Individuals in an Integrated Healthcare Setting. <i>Infectious Diseases: Research and Treatment</i> , 2021, 14, 117863372110187.	1.7	1